Advice is nice, involvement is better Last week BioCentury published a Guest Commentary by David Katz, president & CEO of Lidak Pharmaceuticals, in which he proposed a five-step approach to "Solving the Breakthrough Drugs Quagmire." This week, instead of providing BioCentury's view of Mr. Katz's proposal, we publish a reply by Carl Feldbaum, president of the BIO.

We at BIO welcome vigorous debate, especially when so much is at stake in this on-going health care reform struggle. We are confronting an ambitious, well-intentioned, but somewhat misguided effort of an administration attempting to reconcile the economic, political, and scientific realities of national affordability, universal coverage, and (bio)technological innovation. Unfortunately, innovation is low on the list of priorities of the administration and some members of Congress despite our industry's potential for cures and cost savings.